Skip to main content
Download PDF

Prevalence and varieties of complementary and alternative medicine usage among individuals with pre-dialysis chronic kidney disease in Taiwan: an investigative cross-sectional analysis

BMC Complementary Medicine and Therapies volume 24, Article number: 11 (2024) Cite this article

Abstract

Background

Complementary and alternative medicine (CAM) is frequently used in the general population, yet only limited data are available regarding the prevalence of these medications in patients with chronic kidney disease (CKD). Hence, our study aimed to explore the prevalence and types of CAM in Taiwanese patients with CKD.

Methods

A cross-sectional questionnaire survey was conducted by face-to-face interview of 275 pre-dialysis patients without dialysis treatment or kidney transplant at an outpatient nephrology clinic in Taiwan from March 2021 to June 2023. The study outcomes were the prevalence of CAM, CAM types, reasons for using CAM, and sources of information about CAM.

Results

Overall, 128 patients (46.5%) were using CAM, but no significant differences from non-CAM users in the various CKD stages (p = 0.156) were found. CAM usage was high in the age range of 20–60 years and duration of CKD ≤ 5 years (p < 0.05). The most commonly used type of CAM was nutritional approaches (79.7%), followed by other complementary health approaches (26.6%). The most commonly utilized modalities of CAM were vitamins and minerals (38.3%), and only 27.1% of patients disclosed their CAM use to their physicians. The most common sources of information about CAM were family and friends, cited by 66% of the participants. Health promotion and a proactive attitude were reported by 40% of users as the reasons for using CAM.

Conclusions

The present study provides data on the CAM usage among CKD patients and adds to the increasing evidence on CAM use. Because some of these practices have safety concerns, better education from healthcare providers on the risks and benefits of CAM therapy is needed by CKD patients.

Peer Review reports

Background

Chronic kidney disease (CKD) is an important and noteworthy disease that is emerging as a major public health issue. The global prevalence of CKD was 10.7% (850 million people) in 2021, when it caused 2.4 million deaths and was one of the top 15 cause of mortality worldwide [1]. CKD places a heavy burden on the medical system because it leads to end-stage renal disease (ESRD), which can significantly reduce quality of life (QOL) and is associated with a high mortality rate. Taiwan has a high prevalence of ESRD, and this situation needs greater attention than it is currently receiving [2].

It is important to ameliorate the deterioration in the glomerular filtration rate (GFR) and educate patients to prevent progression of CKD through multidisciplinary care (MDC) education programs. Once patients make the transition from the pre-dialysis phase to the ESRD phase, they are in an irreversible state and the frequency of adverse events increases [3]. Optimal pre-ESRD nephrology care involves early interventions to modify the risk factors of CKD; the management of comorbidities, malnutrition and metabolic complications; and timely provision of dialysis [4]. Since 2006, the implementation of pay-for-performance (P4P) program initiatives in Taiwan for the education and care of individuals in the pre-dialysis phase has gained recognition as a fitting strategy and a promising approach. This method places a strong emphasis on value-based purchasing, utilizing incentives tied to renal indicators, all with the overarching objective of improving healthcare quality and the long-term outlook for patients in CKD stages 3–5 [5,6,7]. This collaborative effort of involves working closely with nephrologists, nurses, pharmacists, and dietitians. However, a significant ongoing challenge is the insufficient adherence to these interventions and the recommended lifestyle changes among CKD patients [8].

The non-curative course of the P4P program has pushed patients with CKD to seek alternative therapies to improve their QOL and maintain residual renal function. Complementary and alternative medicine (CAM) is popular with patients with chronic diseases, as previously found in multiple studies worldwide [9, 10]. The average prevalence of CAM users in 32 countries is 26.4%, and it is as high as 50% in China, the Philippines and South Korea [11]. In certain scenarios, CAM has been noted to offer perceived advantages, including the capacity to manage illnesses, address the side effects of conventional medicine, and enhance the QOL and overall well-being, providing a sense of hope for individuals with CKD [12,13,14,15]. Nevertheless, a rigorous scientific evaluation of CAM is essential, focusing on its safety, effectiveness, and the quality of CAM treatments, as well as the availability of CAM therapies and their rational utilization [16]. Achieving these goals can be further reinforced through the implementation of suitable public policies, legislation, and the integration of CAM into the national health insurance (NHI) system.

In Taiwan, the NHI program provides full reimbursement for traditional Chinese medicine (TCM) treatments, including Chinese herbal medicine (CHM), acupuncture, and traumatology manipulative therapies, and 45.3% of CKD patients have used TCM, according to the NHI research database [17]. However, the data on the use of CAM among CKD patients remain insufficient. We believe that there are still many instances of CKD patients using other CAM modalities without the knowledge of their medical teams. Thus, we conducted this study to determine the prevalence of CAM usage in pre-dialysis CKD patients in Taiwan. We also explored the types of CAM, demographic factors related to CAM usage, and reasons why pre-dialysis patients use CAM.

Materials and methods

Study design and population

This cross-sectional study was conducted at Chang Gung Memorial Hospital (CGMH), a medical center in Kaohsiung, Taiwan, from March 2021 to June 2023. Convenience sampling was adopted in this study to select patients registered in the national pre-ESRD nephrology care program since 2015. Patients older than 20 years, diagnosed as pre-dialysis CKD having eGFR < 45 mL/min/1.73 m2 for more than six months were included in the study. Patients were excluded from the study if they were ESRD receiving dialysis treatment, recipients of a kidney transplant, proteinuria without eGFR staging, refused to sign the consent form or were unfit to be interviewed due to cognitive deficits, psychotic disorders, or inability to perform self-care. Face-to-face interviews using a questionnaire were conducted with selected CKD patients at the nephrology clinic after informed consent was obtained.

The sample size was calculated by z test for the difference between two proportions in G power 3.1.9.2. The estimated prevalence of CAM use in CKD patients was taken as 25.2% based on a published study [10]. For a 95% power confidence level and a 5% significant level confidence limit, the minimum sample size required was 275. The study was approved by the Ethics Committee of the KCGMH (No. 202100097B0). This study complies with the STROBE Statement aimed at Strengthening the Reporting of Observational Studies in Epidemiology guidelines and the required information is presented correctly. The STROBE statement checklist for this study is available in Additional file 1.

Questionnaire

The questionnaire used in the study was adapted from available literature [18,19,20,21]. As shown in Additional file 2, it consisted of 28 items on multiple topics, including 9 items on sociodemographic information of the patients and 3 items related to CKD. The remaining 16 questions focused on the details of CAM, such as the types, frequency, reasons, side effects, compliance, and sources of information about CAM use, as well as the disclosure of use and reasons for nondisclosure to physicians. The face validity of the questionnaire was established by 2 physicians, 2 nurses and 1 epidemiologist, all of whom were academicians with research backgrounds in the area of CAM and nephrology. The content validity index (CVI) score was 0.93. A kappa value of 0.84 was obtained from the final version of the questionnaire, indicating excellent inter-rater reliability.

Definition and classification of CAM

For the purposes of this study, the use of CAM was defined as “any type of CAM used more than twice during the six months after a diagnosis of pre-dialysis.” CAM was classified according to the categories used by the National Center for Complementary and Integrative Health [22]. The three categories are as follows: (1) nutritional approaches such as herbs, vitamins and minerals, and dietary supplements; (2) psychological and physical approaches such as qigong, yoga, acupuncture, exercise, chiropractic, meditation, and tai chi; (3) other complementary health approaches such as Ayurvedic medicine, TCM, homeopathy, and naturopathy. In this study, vitamins and minerals used by patients were not considered CAM if they were prescribed by their physicians. Herbal medicine was defined in this study as an herbal extract purchased by the patients as a decoction, powder or tea from non-medical institutions. Patients were specifically asked if they had used CAM for general health, for the treatment of CKD, or for the treatment of other chronic conditions.

Study procedure

Patients were contacted by the researchers while they were waiting for their appointments at the nephrology clinic. Participants were briefed on the objectives of the study and the definition of CAM prior to the commencement of the interview. They were shown lists and pictures of different types of CAM prior to the interview in order to assist them to provide accurate information on the type(s) of CAM used. Each interview lasted for 10–15 min.

Data analysis

Data analysis was conducted using SPSS version 18 (IBM Corp., Armonk, NY, USA). The data were presented in terms of frequencies and percentages. To evaluate the relationship between CAM utilization and sociodemographic variables, as well as its association with various groups of pre-dialysis patients, Pearson's Chi-squared test or Fisher's exact test was employed. A significance level of p < 0.05 was applied to all analyses.

Result

Out of the 300 pre-dialysis patients initially approached for the study, 275 consented to participate, giving a response rate of 91.7%. The majority of the patients were male, were aged more than 60 years, had a low education level, and were married. The sociodemographic details of the study participants are presented in Table 1. Among all the sociodemographic variables, only the age range of 20–60 years old and duration of CKD ≤ 5 years were significantly high in the CAM group (p < 0.05).

Table 1 Sociodemographic characteristics of CAM and non-CAM users with pre-dialysis
Full size table

Table 2 presents the patient distribution by severity of CKD. Most of the patients were in Stage 3b of CKD (n = 129, 46.9%), followed by Stage 4 (n = 95, 34.5%) and stage 5 (n = 51, 18.5%). Among the 275 respondents, 46.5% reported using at least one type of CAM more than three times in the previous 6 months. There were no significant associations between the different groups of patients by CKD severity level and CAM use. In addition, we analyzed the CAM use among different groups of patients with pre-dialysis stratifying by age and duration of CKD as shown in Table 3. There were no significant associations between the different groups of patients by CKD severity level and CAM use stratifying by the age. However, patients with CKD duration ≤ 5 years have significant association between the different groups of patients by CKD severity level and CAM use (p = 0.039).

Table 2 CAM use among different groups of patients with pre-dialysis
Full size table
Table 3 Comparison of age and duration in different CKD stages between CAM users and non-users
Full size table

As for the types of CAM used by the respondents, this study found that nutritional approaches (n = 102, 79.7%) were the most common type of CAM used, followed by other complementary health approaches (n = 34, 26.6%). A small portion used mind and body practices (n = 14, 11%). In the subgroup analysis, it was found that nutritional approaches were more commonly used by patients in stage 3b (83.6%) and stage 5 (87.5%); however, none of the psychological and physical approaches were reported by patients in stage 5 (Table 4).

Table 4 Types of CAM used by different groups of pre-dialysis patients (n = 128)
Full size table

Table 5 lists the top 10 CAM modalities used by the various groups of pre-dialysis patients. Vitamins and minerals (38.3%) and CHM (21.9%) were the most common nutritional and other complementary health approaches used, respectively. Among the users of vitamin and mineral users in different stages, those in stage 5 were the largest group (41.7%). However, in comparison with the stage 3b and 4 patients, stage 5 patients were noted to have the lowest usage of other CAM approaches. Interestingly, higher percentages of CAM, including CHM (27%), lutein (27%), acupuncture (16.2%), and exercise (10.8%), were observed in the stage 4 group than in the other patient groups. None reported using herbal medicines or secret recipes.

Table 5 Top 10 common CAM modalities used by different groups of pre-dialysis patients (n = 128)
Full size table

Two-thirds (66%) of the respondents obtained information about CAM from their family and friends. Some of them depended on information from the internet (6%) and other media sources such television or newspapers (19%). Only 7% of the respondents had ever asked healthcare professionals about CAM (Fig. 1).

Fig. 1
figure 1

Sources of information regarding CAM. Abbreviation: CAM, complementary and alternative medicine

Full size image

When asked about their purposes in using CAM (Fig. 2), the majority of the patients reported that their usage was driven by a desire for improvement of their general health (n = 92, 44.2%), followed by a proactive attitude (n = 86, 41.3%). Small minorities used CAM to treat their CKD (6.3%) or considered conventional treatment to be too toxic or damaging (6.3%). Only 4 patients (1.9%) reported using CAM because they were disappointed with conventional treatment.

Fig. 2
figure 2

Primary reason for CAM use. Abbreviation: CAM, complementary and alternative medicine

Full size image

As high as 72.9% (n = 92) of the 125 CAM users among the pre-dialysis patients did not disclose their CAM use to their physicians. Upon further investigation, the most common reason stated for the non-disclosure was that patients feared that the physicians would disapprove of their use of CAM (44%). Another 39% of the patients thought that their physicians did not need to know such details, while 17% of the patients answered that their physicians did not inquire about CAM use (Fig. 3).

Fig. 3
figure 3

Reasons for non-disclosure of CAM use to physicians. Abbreviation: CAM, complementary and alternative medicine

Full size image

More than half (62.5%) of the CAM users expressed satisfaction and 37.5% (n = 48) were neutral on the topic of CAM use. No users reported experiencing adverse effects (e.g., vomiting and diarrhea) from CAM use. Compliance with modern medical treatment was affected in 3.9% of the CAM users.

Discussion

In our sample population, 46.5% of the patients with pre-dialysis CKD reported having used CAM within half a year of the survey. The most common modality used by patients was nutritional approaches. A majority of patients felt that the CAM therapy was very important for their general health. An estimated two-thirds of the patients obtained CAM information from their family and friends, and 72.9% of them did not disclose their CAM use to their physicians.

In comparison to other international surveys among similar CKD patients, the prevalence of CAM use was lower in our study than in Egypt (64%) [23] but higher than in Turkey (25.2%) [9], Malaysia (29%) [24] and Korea (24.6%) [25]. The variation in findings can be attributed to disparities in how CAM usage is defined, the diverse geographical locations, cultural influences, and socioeconomic statuses considered in these studies. Additionally, the differing official policy stances and empirical support for CAM use within the CKD population could play a role in this discrepancy. While most of the research conducted to identify patterns of CAM usage have focused only on the general CKD population [9, 23,24,25], limited information on the prevalence of CAM usage by pre-dialysis patients utilizing preventive services has been reported. To the best of our knowledge, this is the first study to be reported from Taiwan.

Upon commencement of the P4P program, the care indicators include renal function maintenance, improvement of proteinuria, continuous MDC, pre-inserted hemodialysis (HD) access, and pre-ESRD management and education [26]. Although the P4P program can significantly mitigate the HD events, hospitalization, and all-cause mortality in patients with CKD stages 3–5 compared to patients who do not receive it [7], such medical care is not completely achievable. A recent study found that only 37% of HD institutes that intensively performed pre-ESRD nephrology care optimally responded to anemia and prepared an arteriovenous fistula for HD [27]. The keys to success have been reported as a more positive attitude toward the disease, a willingness to cooperate with treatment adherence, and self-management, such as the adoption of nutritional counseling, lifestyle behavior changes, and avoidance of NSAIDS, nephrotoxins and unproven therapies [28]. Even under the comprehensive pre-ESRD nephrology care, the additional choice of CAM use is common.

In our study, the prevalence of CAM usage was high in the group aged 20–60 years, according to the distribution. This finding was consistent with a study by Birdee et al. [29] and Castelino et al. [30], which showed that CAM usage was higher in young and middle-aged patients than in other age groups. The prevalence of CKD is higher in this age group due to a higher incidence of chronic illness such as diabetes and hypertension [31]. Meanwhile, the use of CAM also varies by duration of CKD. Our study found that the prevalence of CAM usage in patients with stages 3b, 4, and 5 show no significant differences compared with subgroups of non-CAM users. While most of the studies conducted by the national surveys of some countries to report the high prevalence of CAM usage have been at advanced stages of CKD [24, 30, 32], very few surveys have reported CAM prevalence among patients with middle stage. To address this gap, we further analyzed the usage of CAM according to different stage groups stratifying by age and duration of CKD. Our findings revealed a significant influence between CAM usage and patients diagnosed within 5 years of CKD 3b, whereas age was not relevant. This situation may be explained by participants who are diagnosed with CKD 3b in the P4P program more willing to spend on CAM methods in conjunction with their conventional therapies. Notably, the current clinical practice guidelines primarily focus on ambulatory care, including monitoring underlying conditions and implementing diet and lifestyle controls [33, 34]. At a more advanced stage, the intervention of conventional medications increases, and the illness lasts longer, there are signs of a decline in CAM treatments.

The prevalence found in our study was relatively low compared to the CAM usage in the general population (75.5–86.9%) in Taiwan [35,36,37] and in patients with other chronic illnesses [38, 39]. This difference may be due to increased public awareness of the risk of kidney problems with CAM use following media campaigns. Meanwhile, the use of CAM to treat kidney disease was found to be low in our study (6.3%), as also found in another study in Turkey [9]. The majority of the patients used CAM to promote their health (44.2%) and maintain a proactive attitude (41.3%). This finding may be partially related to the early patient education, in which patients with pre-dialysis learn that disease progression is irreversible. It also confirms that patients do not use CAM to replace conventional medicine but rather to complement it. However, the diverse cultural beliefs in Taiwan still lead to misconduct in looking for health behaviors, such as purchasing CAM products and following guidance from non-medical sources [18]. Our study found that over 70% of the study participants learned about CAM therapies from family/friends and about 25% from the media. The main reason why patients did not inform their physicians about their CAM use was concerns about physicians' disapproval of the use of CAM, which reflects poor patient–physician communication. Many of the CAM users kept their use of CAM from their physicians, as reported in the present study and other similar studies [23, 40, 41], simply because their healthcare providers did not inquire about it. Therefore, healthcare providers must be aware of CAM usage in their patients and inquire about such practices, as CAM may interact with prescribed medications and affect patient compliance with the care plan [42, 43].

In this study, 79.7% of the CAM users reported having used nutritional supplements, and most of these frequently relied on vitamins and minerals, lutein, fish oil, glucosamine, calcium, etc. Patients with CKD may experience vitamin deficiency, hypertension, hyperphosphatemia, anorexia, as well as protein-energy wasting. Medical nutritional therapy is recommended to delay CKD progression and to prevent and/or treat malnutrition and wasting [44]. Otherwise, our results should serve as a reminder to healthcare professionals that the proportion of patients purchasing over-the-counter medications cannot be ignored, and clinicians must be aware of serious possible sequelae. For example, multivitamins are not recommended in CKD stages 3–5 because many provide higher dosages of vitamins A, E, and K, which can lead to anemia, liver dysfunction, heart failure, or coagulopathy [45, 46]. Excessive vitamin C intake can increase oxalate excretion, increasing the risk of kidney stones and body tissue deposition [47]. Minerals such as potassium, calcium, magnesium and phosphorus also have the potential to worsen kidney function [48]. Even though fish oil has been proven to improve blood pressure, lower blood triglycerides, reduce cardiovascular events, and at the same time reduce the inflammatory response of the kidneys and protect them [49], excessive use still entails a risk of bleeding [50]. Although most dietary supplements are known to have antioxidant effects which, through multiple mechanisms, can prevent aggravated glomerulosclerosis and fibrosis during CKD [51], there is little evidence that they improve CKD outcomes [52].

CHM and acupuncture use were reported by 21.9% and 7.8% of the CAM users, respectively. These rates of TCM consumption are higher than those reported in an earlier survey of CKD patients in northern Taiwan [53]. In a chart review survey of 8459 pre-dialysis patients [53], only 4.8% were currently using TCM and preferred CHM over other TCM services. Although certain CHM therapies analyzed in population-based studies have scientific merit and evidence supporting their use [17], some traditional herbs lack such support and might be potentially harmful to patients [54, 55]. Unexpectedly, the use of herbs/recipes was reported by 0% of the CAM users in the present study. This result shows that our pre-dialysis patients were less likely to seek non-prescribed CHM from herbal and supplement stores. Since 1995, the CHM prescribed by TCM practitioners under the NHI program has been mostly a scientifically-designed powder, which is convenient and well preserved, has a standardized GMP manufacturing process, and meets standards for heavy metals, flatoxin, and pesticide residues [56]. The prescribed CHM is known to reduce the mortality rate in patients with CKD by 40% as compared with non-users [57]. Other studies also reflect that CKD patients who receive proper CHM prescriptions might obtain more beneficial effects, including maintained eGFR in the advanced stage [58], improved QOL [53], and prolonged time to dialysis in patients with diabetes [59]. Patients with CKD and several comorbidities may simultaneously take many different medications. Therefore, the additional intake of either nutritional products or CHM for CKD is usually complicated and needs to be integrated due to the increased risk of side effects from drug–nutrient or drug–herb interactions.

Our study offers valuable insights to healthcare providers regarding the utilization of CAM among pre-dialysis CKD patients. It is imperative to conduct comprehensive research to understand the frequency and interactions of CAM therapies with prescribed medications in CKD patients. To achieve this, the MDC team should comprise experts well-versed in CAM, capable of supplying relevant evidence regarding its advantages and potential risks. Moreover, the persistent use of CAM in current populations is a critical aspect to monitor in relation to the progression of future diseases.

This study has several limitations. First, as it was conducted in southern Taiwan at a hospital with an outpatient nephrology clinic and the sample was recruited by the convenience sampling method, the results cannot be generalized to other populations. Second, it is possible that the level of use of CAM reported was lower than the actual level, as these P4P participants might have been educated to be cautious about CAM usage. Third, there was also the possibility of recall bias regarding the use of CAM in this cross-sectional design. Besides, the Neyman bias is another possible limitation, because we could not identify whether the participants had used CAM in the past or only in the present. Therefore, the results of this study may be affected by prevalence–incidence (Neyman’s) bias. Further prospective cohort studies, which select the newly identified cases as study participants, will effectively avoid Neyman bias.

Conclusion

CAM use, in particular nutritional approaches, is common in patients with pre-dialysis on the P4P program in Taiwan and is used by a greater percentage of non-elderly group and shorter duration of CKD. Some of the CAM used by patients can potentially lead to adverse side effects or produce unintended interactions with conventional medications. The majority of the patients did not disclose their use of CAM to their physicians because they were worried that the physician would prohibit their use. Thus, it is critical for healthcare professionals to integrate information from patients’ CAM usage and educate them according to evidence-based practice. More studies concerning the safety and efficacy of CAM in the management of CKD in the P4P program should be conducted to achieve better healthcare quality and disease outcomes if any benefits are supported.

Availability of data and materials

The datasets used or analyzed (or both) in the study are available from the corresponding author upon reasonable request.

Abbreviations

CAM:

Complementary and alternative medicine

CHM:

Chinese herbal medicine

CKD:

Chronic kidney disease

CVI:

Content validity index

ESRD:

End-stage renal disease

GFR:

Glomerular filtration rate

HD:

Hemodialysis

MDC:

Multidisciplinary care

NHI:

National Health Insurance

P4P:

Pay for performance

QOL:

Quality of life

TCM:

Traditional Chinese medicine

References

  1. International Society of Nephrology. [https://www.theisn.org/edigest-nov-2021/]. Accessed 1 Dec 2023.

  2. Tsai MH, Hsu CY, Lin MY, Yen MF, Chen HH, Chiu YH, Hwang SJ. Incidence, Prevalence, and Duration of Chronic Kidney Disease in Taiwan: Results from a Community-Based Screening Program of 106,094 Individuals. Nephron. 2018;140(3):175–84.

    Article  PubMed  Google Scholar 

  3. Sharief S, Hsu CY. The Transition From the Pre-ESRD to ESRD Phase of CKD: Much Remains to Be Learned. Am J Kidney Dis. 2017;69(1):8–10.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998;31(3):398–417.

    Article  CAS  PubMed  Google Scholar 

  5. Lin MY, Cheng LJ, Chiu YW, Hsieh HM, Wu PH, Lin YT, Wang SL, Jian FX, Hsu CC, Yang SA, et al. Effect of national pre-ESRD care program on expenditures and mortality in incident dialysis patients: A population-based study. PLoS ONE. 2018;13(6):e0198387.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chou CL, Chung CH, Chiu HW, Liao CT, Wu CC, Hsu YH, Chien WC. Association of pre-ESRD care education with patient outcomes in a 10-year longitudinal study of patients with CKD stages 3–5 in Taiwan. Sci Rep. 2021;11(1):22602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lin MY, Chang MY, Wu PY, Wu PH, Lin MH, Hsu CC, Chang JM, Hwang SJ, Chiu YW. Multidisciplinary care program in pre-end-stage kidney disease from 2010 to 2018 in Taiwan. J Formos Med Assoc. 2022; 121 Suppl 1:S64-s72.

  8. Fishbane S, Hazzan AD, Halinski C, Mathew AT. Challenges and opportunities in late-stage chronic kidney disease. Clin Kidney J. 2015;8(1):54–60.

    Article  PubMed  Google Scholar 

  9. Akyol AD, Yildirim Y, Toker E, Yavuz B. The use of complementary and alternative medicine among chronic renal failure patients. J Clin Nurs. 2011;20(7–8):1035–43.

    Article  PubMed  Google Scholar 

  10. Mbizo J, Okafor A, Sutton MA, Leyva B, Stone LM, Olaku O. Complementary and alternative medicine use among persons with multiple chronic conditions: results from the 2012 National Health Interview Survey. BMC Complement Altern Med. 2018;18(1):281.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Peltzer K, Pengpid S. Prevalence and Determinants of Traditional, Complementary and Alternative Medicine Provider Use among Adults from 32 Countries. Chin J Integr Med. 2018;24(8):584–90.

    Article  PubMed  Google Scholar 

  12. Chu SWF, Yeam CT, Low LL, Tay WY, Foo WYM, Seng JJB. The role of mind-body interventions in pre-dialysis chronic kidney disease and dialysis patients - A systematic review of literature. Complement Ther Med. 2021;57:102652.

    Article  PubMed  Google Scholar 

  13. Yeam CT, Yo TE, Tan YLC, Liew A, Seng JJB. Complementary and alternative medicine therapies for uremic pruritus - A systematic review of randomized controlled trials. Complement Ther Med. 2021;56:102609.

    Article  PubMed  Google Scholar 

  14. Chu SWF, Ng WJ, Yeam CT, Khan RQ, Low LL, Quah JHM, Foo WYM, Seng JJB. Manipulative and body-based methods in chronic kidney disease patients: A systematic review of randomized controlled trials. Complement Ther Clin Pract. 2022;48:101593.

    Article  PubMed  Google Scholar 

  15. Teo WY, Chu SWF, Chow LY, Yeam CT, Low LL, Quah JHM, Foo M, Seng JJB. Role of Alternative Medical Systems in Adult Chronic Kidney Disease Patients: A Systematic Review of Literature. Cureus. 2022;14(12):e32874.

    PubMed  PubMed Central  Google Scholar 

  16. White A, Boon H, Alraek T, Lewith G, Liu J, Norheim A, Steinsbekk A, Yamashita H, Fønnebø V. Reducing the risk of complementary and alternative medicine (CAM): Challenges and priorities. Eur J Integr Med. 2013;6(4):404–8.

  17. Lin MY, Chiu YW, Chang JS, Lin HL, Lee CT, Chiu GF, Kuo MC, Wu MT, Chen HC, Hwang SJ. Association of prescribed Chinese herbal medicine use with risk of end-stage renal disease in patients with chronic kidney disease. Kidney Int. 2015;88(6):1365–73.

    Article  PubMed  Google Scholar 

  18. Chin CY, Chen YH, Wu SC, Liu CT, Lee YF, Tsai MY. Complementary and Alternative Medicine Use in Breast Cancer Patients at a Medical Center in Taiwan: A Cross-Sectional Study. Integr Cancer Ther. 2020;19:1534735420983910.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Chang M-Y, Liu C-Y, Chu M-C, Wu T-M, Chen M-L, Chu M-L. Conditions for the use of complementary and alternative medicine in Taiwan: a nationwide survey analysis for 2011. Taiwan Gong Gong Wei Sheng Za Zhi. 2013;32(1):85–99.

    Google Scholar 

  20. Erku DA. Complementary and Alternative Medicine Use and Its Association with Quality of Life among Cancer Patients Receiving Chemotherapy in Ethiopia: A Cross-Sectional Study. Evid Based Complement Alternat Med. 2016;2016:2809875.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nowack R, Ballé C, Birnkammer F, Koch W, Sessler R, Birck R. Complementary and alternative medications consumed by renal patients in southern Germany. J Renal Nutr. 2009;19(3):211–9.

    Article  Google Scholar 

  22. Complementary, alternative, or integrative health: what's in a name (n.d.) [https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name]. Accessed 1 Dec 2023.

  23. Osman NA, Hassanein SM, Leil MM, NasrAllah MM. Complementary and Alternative Medicine Use Among Patients With Chronic Kidney Disease and Kidney Transplant Recipients. J Renal Nutr. 2015;25(6):466–71.

    Article  Google Scholar 

  24. Muhammad Yusuf AS, Abdul Halim AG, Shamsul Azhar S. The Use of Complementary and Alternative Medicine among Malaysian Chronic Kidney Disease Patients. Med Health. 2019;14:219–34.

    Article  Google Scholar 

  25. Jeon HO, Kim BH, Kim O. Illness uncertainty and complementary and alternative medicine use in patients undergoing hemodialysis. Nurs Health Sci. 2019;21(3):375–81.

    Article  PubMed  Google Scholar 

  26. Wei SY, Chang YY, Mau LW, Lin MY, Chiu HC, Tsai JC, Huang CJ, Chen HC, Hwang SJ. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs. Nephrology (Carlton). 2010;15(1):108–15.

    Article  CAS  PubMed  Google Scholar 

  27. Hao H, Lovasik BP, Pastan SO, Chang HH, Chowdhury R, Patzer RE. Geographic variation and neighborhood factors are associated with low rates of pre-end-stage renal disease nephrology care. Kidney Int. 2015;88(3):614–21.

    Article  PubMed  Google Scholar 

  28. Chen YR, Yang Y, Wang SC, Chiu PF, Chou WY, Lin CY, Chang JM, Chen TW, Ferng SH, Lin CL. Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study. Nephrol Dial Transplant. 2013;28(3):671–82.

    Article  CAS  PubMed  Google Scholar 

  29. Birdee GS, Phillips RS, Brown RS. Use of Complementary and Alternative Medicine among Patients with End-Stage Renal Disease. Evid Based Complement Alternat Med. 2013;2013: 654109.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Castelino LR, Nayak-Rao S, Shenoy MP. Prevalence of use of complementary and alternative medicine in chronic kidney disease: A cross-sectional single-center study from South India. Saudi J Kidney Dis Transpl. 2019;30(1):185–93.

    Article  PubMed  Google Scholar 

  31. Barraco D, Valencia G, Riba AL, Nareddy S, Draus CB, Schwartz SM. Complementary and alternative medicine (CAM) use patterns and disclosure to physicians in acute coronary syndromes patients. Complement Ther Med. 2005;13(1):34–40.

    Article  PubMed  Google Scholar 

  32. Shamsuddin N, Karuppannan M, Hafiz Wan Md Adnan WA, Farooqui M, Gnanasan S. Pattern of complementary and alternative medicine (CAM) use among patients with chronic kidney disease. Complement Ther Clin Pract. 2019; 37:86-92.

  33. Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159(12):835–47.

    PubMed  Google Scholar 

  34. Baker LA, March DS, Wilkinson TJ, Billany RE, Bishop NC, Castle EM, Chilcot J, Davies MD, Graham-Brown MPM, Greenwood SA, et al. Clinical practice guideline exercise and lifestyle in chronic kidney disease. BMC Nephrol. 2022;23(1):75.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Lin K-C, Chen M-L, Yeh M-L, Hsu C-H, Chen Y-L, Chou P. Prevalence, Pattern, and Predictors of Use of Complementary and Alternative Medicine in Taiwan. Taiwan J Public Health. 2009;28(1):53–68.

    CAS  Google Scholar 

  36. Yeh ML, Lin KC, Chen HH, Wang YJ, Huang YC. Use of traditional medicine and complementary and alternative medicine in Taiwan: a multilevel analysis. Holist Nurs Pract. 2015;29(2):87–95.

    Article  PubMed  Google Scholar 

  37. Chang MY, Liu CY, Chen HY. Changes in the use of complementary and alternative medicine in Taiwan: a comparison study of 2007 and 2011. Complement Ther Med. 2014;22(3):489–99.

    Article  PubMed  Google Scholar 

  38. Chang HY, Wallis M, Tiralongo E. Use of Complementary and Alternative Medicine among People with Type 2 Diabetes in Taiwan: A Cross-Sectional Survey. Evid Based Complement Alternat Med. 2011;2011:983792.

  39. Hsu MC, Creedy D, Moyle W, Venturato L, Tsay SL, Ouyang WC. Use of Complementary and Alternative Medicine among adult patients for depression in Taiwan. J Affect Disord. 2008;111(2–3):360–5.

    Article  PubMed  Google Scholar 

  40. Tangkiatkumjai M, Boardman H, Praditpornsilpa K, Walker DM. Prevalence of herbal and dietary supplement usage in Thai outpatients with chronic kidney disease: a cross-sectional survey. BMC Complement Altern Med. 2013;13:153.

    Article  PubMed  PubMed Central  Google Scholar 

  41. AlAnizy L, AlMatham K, Al Basheer A, AlFayyad I. Complementary and Alternative Medicine Practice Among Saudi Patients with Chronic Kidney Disease: A Cross-Sectional Study. Int J Nephrol Renov Dis. 2020;13:11–8.

    Article  Google Scholar 

  42. Koithan M. Let’s Talk about Complementary and Alternative Therapies. J Nurse Pract. 2009;5(3):214–5.

  43. Schofield P, Diggens J, Charleson C, Marigliani R, Jefford M. Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Patient Educ Couns. 2010;79(2):143–51.

    Article  PubMed  Google Scholar 

  44. JDK, SGM. Nutritional management of renal disease. In. Edited by JDK, SGM. Baltimore: Williams and Wilkins; 2004.

  45. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan W, Fouque D, Friedman AN, Ghaddar S, Goldstein-Fuchs DJ, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3):S1–107.

  46. Handelman GJ, Levin NW. Guidelines for vitamin supplements in chronic kidney disease patients: what is the evidence? J Renal Nutr. 2011;21(1):117–9.

    Article  CAS  Google Scholar 

  47. Baxmann AC, De OGMC, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int. 2003;63(3):1066–71.

    Article  CAS  PubMed  Google Scholar 

  48. Messa P. Dietary Habits, Vitamin and Mineral Supplements in Patients with Chronic Kidney Disease (CKD). Nutrients. 2020;12(12):3817.

  49. Fazelian S, Moradi F, Agah S, Hoseini A, Heydari H, Morvaridzadeh M, Omidi A, Pizarro AB, Ghafouri A, Heshmati J. Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2021;22(1):160.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Saglimbene VM, Wong G, van Zwieten A, Palmer SC, Ruospo M, Natale P, Campbell K, Teixeira-Pinto A, Craig JC, Strippoli GFM. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2020;39(2):358–68.

    Article  CAS  PubMed  Google Scholar 

  51. Martello E, Perondi F, Bruni N, Bisanzio D, Meineri G, Lippi I. Chronic Kidney Disease and Dietary Supplementation: Effects on Inflammation and Oxidative Stress. Vet Sci. 2021;8(11):277.

  52. Lin PC, Chou CL, Ou SH, Fang TC, Chen JS. Systematic Review of Nutrition Supplements in Chronic Kidney Diseases: A GRADE Approach. Nutrients. 2021;13(2):469.

  53. Yang T-H, Chen H-Y, Yang S-H, Lin Y-H, Fang J-T, Hung C-C, Chen J-L. Utilization Pattern for Traditional Chinese Medicine among Late Stage Chronic Kidney Disease Patients: A Hospital-Based Cross-sectional Study. J Chinese Med. 2014;25(1):41–58.

    Google Scholar 

  54. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.

    Article  PubMed  Google Scholar 

  55. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. Am J Kidney Dis. 2007;49(5):626–33.

    Article  PubMed  Google Scholar 

  56. Liu YW, Hsu YT, Lee WC, Tsai MY. Review of Traditional Chinese Medicines for Common Complications Related to Hemodialysis: An Evidence-Based Perspective. Evid Based Complement Alternat Med. 2021;2021:9953986.

    PubMed  PubMed Central  Google Scholar 

  57. Hsieh CF, Huang SL, Chen CL, Chen WT, Chang HC, Wu ML, Yang CC. Increased risk of chronic kidney disease among users of non-prescribed Chinese herbal medicine in Taiwan. Prev Med. 2012;55(2):155–9.

    Article  PubMed  Google Scholar 

  58. Chen W, Chen HY, Yang YH, Yang SH, Yang CW, Wu YH, Chen JL. An Investigation of the Prescription Patterns of Chinese Herbal Products for Chronic Glomerulonephritis Patients: A Hospital-Based Cross-Sectional Study. Evid Based Complement Alternat Med. 2018;2018:5080764.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Hsu PC, Tsai YT, Lai JN, Wu CT, Lin SK, Huang CY. Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol. 2014;156:358–64.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge all members in the CKD team of Kaohsiung Chang Gung Memorial Hospital for their kind help.

Funding

This study was funded by Chang Gung Memorial Hospital under grant number CMRPG-8L1311 & -8M0971. The funders have had no role in study design or the trial design, manuscript writing, or decision making on publication.

Author information

Authors and Affiliations

  1. Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and, Chang Gung University College of Medicine, No. 123 Dapi Rd., Niaosong Dist., Kaohsiung, 83301, Taiwan

    Ming-Yen Tsai, Chieh-Ying Chin & Yung-Tang Hsu

  2. Department of Medical Research, China Medical University Hospital and School of Chinese Medicine, China Medical University, Taichung, 41354, Taiwan

    Yu-Chuen Huang

  3. Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan

    Ben-Chung Cheng & Wen-Chin Lee

  4. Department of Nursing, MeiHo University, Pingtung, 912009, Taiwan

    Chieh-Ying Chin

  5. Kaohsiung Municipal Feng Shan Hospital—Under the management of Chang Gung Medical Foundation, Kaohsiung, 830025, Taiwan

    Chieh-Ying Chin

Authors
  1. Ming-Yen Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Chuen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben-Chung Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chieh-Ying Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yung-Tang Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen-Chin Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design: MYT, WCL, and BCC. Data analysis planning: YCH, CYC, and YTH. Drafting of the manuscript: MYT. Critical revisions: MYT, WCL, and YCH. Final approval of the article: all authors. Obtaining funding: MYT, who is responsible for the integrity of the work as a whole.

Corresponding authors

Correspondence to Ming-Yen Tsai or Wen-Chin Lee.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee at Kaohsiung Chang Gung Memorial Hospital (registration number 202100097B0) as well as each research facility. This study was performed in accordance with the tenets set forth in the Declaration of Helsinki. All enrolled patients provided informed written consent prior to participation.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies.

Additional file 2. 

Complementary and alternative medicine questionnaire.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsai, MY., Huang, YC., Cheng, BC. et al. Prevalence and varieties of complementary and alternative medicine usage among individuals with pre-dialysis chronic kidney disease in Taiwan: an investigative cross-sectional analysis. BMC Complement Med Ther 24, 11 (2024). https://doi.org/10.1186/s12906-023-04311-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-023-04311-2

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us